Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2025 Revenue
TMCIPONTE VEDRA, Fla., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced its preliminary, unaudited fourth quarter and full-year 2025 revenue results.
Treace Medical to Host Investor Day Highlighting New Products on September 3, 2025
TMCIPONTE VEDRA, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced plans to host an investor day at 9:00 am E.T. on September 3, 2025, in New York, New York. The event will include presentations by members of management and experienced surgeon users, highlighting their experiences with the expanded technology portfolio.
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Treace Medical
TMCINEW YORK--(BUSINESS WIRE)---- $TMCI #ClassAction--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NASDAQ: TMCI) and reminds investors of the June 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
UBS Maintains Neutral on Treace Medical Concepts, Lowers Price Target to $8.6
TMCITreace Medical Concepts Affirms FY2025 Sales Guidance of $224.00M-$230.00M vs $227.53M Est
TMCITreace Medical Concepts Q1 EPS $(0.25) Beats $(0.30) Estimate, Sales $52.57M Beat $52.07M Estimate
TMCITruist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $8
TMCITreace Highlights Clinical Study Data On Lapiplasty And Adductoplasty Outcomes At The 2025 ACFAS Annual Scientific Conference
TMCITruist Securities Maintains Hold on Treace Medical Concepts, Lowers Price Target to $9.5
TMCIDeep Dive Into Treace Medical Concepts Stock: Analyst Perspectives (4 Ratings)
TMCITruist Securities Maintains Hold on Treace Medical Concepts, Raises Price Target to $10
TMCITreace Medical Concepts Sees FY2025 Sales $224.000M-$230.000M vs $225.67M Est
TMCITreace Medical Concepts Q4 EPS $(0.01) Beats $(0.04) Estimate, Sales $68.71M Beat $67.16M Estimate
TMCITreace Medical Concepts Announces Preliminary Q4 Revenue Of $68.4M-$68.8M, Up 10% YoY; FY24 Revenue Of $209M-$209.4M, Up 12%; Added 280 Surgeons, Now 3,135 Active; Plans Innovative Product Launches In 2025
TMCIStifel Maintains Hold on Treace Medical Concepts, Raises Price Target to $8
TMCITreace Medical Concepts Q3 2024 GAAP EPS $(0.25) Beats $(0.27) Estimate, Sales $45.086M Beat $43.484M Estimate
TMCITreace Medical Concepts Raises FY2024 Sales Guidance from $201.00M-211.00M to $204.00M-211.00M
TMCIEarnings Preview For Treace Medical Concepts
TMCIUnveiling 6 Analyst Insights On Treace Medical Concepts
TMCIUBS Downgrades Treace Medical Concepts to Neutral, Lowers Price Target to $6.5
TMCITreace Announces Updated Interim Analysis From The ALIGN3D Clinical Study at the 2022 American Orthopaedic Foot & Ankle Society Annual Meeting
TMCITreace Medical Concepts Reports Secured New 5-Year, $150M Loan Arrangement With MidCap Financial
TMCI